Kosan BioSciences -- KOSN | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Kosan BioSciences -- KOSN

An SI Board Since May 2001

Posts	SubjectMarks	Bans	Symbol
933	40	0	KOSN

Emcee: tuck	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
483	Hmmm . . . time to do an IP check here? I hate those, they're so time c	tuck	-	7/15/2004
482	J Med Chem. 2004 Jul 15;47(15):3865-73. Related Articles,Links Synthesis and	Biomaven	-	7/15/2004
481	Have to get back to you on that (I had a tiny holding in Neutec as I liked the i	nigel bates	-	7/14/2004
480	could you review the project? the rationale? an abstract pointer? thanks! ca	scaram(o)uche	-	7/14/2004
479	<i>Hsp90</i> Neutec are seeking a partner to trial 'Mycograb'	nigel bates	-	7/14/2004
478	Kosan's New 17-AAG Formulation Enters Clinic Wednesday July 14, 7:30 am ET	scaram(o)uche	-	7/14/2004
477	(OT) That's why I like Genencor and Diversa - they get to sell stuff witho	nigel bates	-	6/30/2004
476	>> any biologist will have a blast, exploring a stream that vents on the s	scaram(o)uche	-	6/29/2004
475	I did send a mildly worded rocket to the SEC, not because a lot of money is invo	tom pope	-	6/26/2004
474	<i>after a first line therapy that has such associated toxicity</i>	Biomaven	-	6/25/2004
473	>> I saw Austin and figured it was that one << Yeah, that's whe	scaram(o)uche	-	6/25/2004
472	OT Starlit nights and not a sound but the critters. ("A Younger Girl"	quidditch	-	6/25/2004
471	Thanks, Tuck. I'm trying to figure out why KOSN would design the trial as a	quidditch	-	6/25/2004
470	[Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusi	tuck	-	6/25/2004
469	Thank you, Peter. I wonder how KOSN/Roche came up with the trial design.	quidditch	-	6/24/2004
468	quid, As tuck has posted, neuropathy is primarily a problem for the platinum dr	Biomaven	-	6/24/2004
467	Peter, I think you are basically right. BMS' Epo B seems to have similar p	tuck	-	6/24/2004
466	Thanks, Peter. A couple of follow-up questions: How does this affect the poten	quidditch	-	6/24/2004
465	A repeat of a post I made on the Valuation thread in response to a question abou	Biomaven	-	6/24/2004
464	enforcement@sec.gov is the place to complain to. Message 20245982 Peter	Biomaven	-	6/23/2004
463	It was great. 55 miles in by (good) dirt road, not another vehicle. Ditto goin	scaram(o)uche	-	6/23/2004
462	As well, a 200,000 option grant to the svp, just filed. In fairness to kosn, no	keokalani'nui	-	6/22/2004
461	Something is fishy with the advance sale on huge volume last week. I am lucky I	jayhawk969	-	6/22/2004
460	The ticker told the story. Roche, Kosan to end colorectal cancer drug study Tue	keokalani'nui	-	6/22/2004
459	Nigel, thanks for posting that. eom	quidditch	-	6/21/2004

Go to reply# or date (mm/dd/yy):